Sherlock Biosciences: Martin Madaus

Sherlock Biosciences has appointed Martin Madaus as chief operations officer. Madaus brings nearly 30 years of industry experience leading diagnostics companies across all stages of development through commercialization, and will lead Sherlock's business operations functions while supporting the company to scale to a fully functional commercial organization.

Madaus most recently served as interim CEO and executive chairman at Ultivue and Emulate Bio. He also served as chairman and CEO of Ortho Clinical Diagnostics from 2014 to 2019, leading the buyout through the Carlyle Group, where he continues to serve as operating executive. Prior to that, he served as president, chairman, and CEO of Millipore, which was acquired by Merck KGaA, and as CEO of Roche Diagnostics North America. Madaus also has extensive public and private company board experience and currently serves on the boards of Quanterix, Ultivue, Emulate Bio, and Candela Medical.